Navigation Links
Why Our Kids Can't Breathe in Our Communities
Date:5/13/2008

New report provides blueprint to fight the environmental triggers of childhood asthma

OAKLAND, Calif., May 13 /PRNewswire-USNewswire/ -- Our homes, schools, playgrounds and neighborhoods are riddled with preventable asthma triggers that leave millions of children gasping for air. But a new report released today by PolicyLink and The California Endowment lays out a plan for what we all can do to make our children's air safer and healthier.

The new report, Breathing Easy from Home to School: Fighting the Environmental Triggers of Childhood Asthma, provides a blueprint for dramatically reducing the community factors that contribute to asthma development and spark asthma attacks. The full report is available at http://www.policylink.org/breathingeasy.

The asthma epidemic is clearly a crisis, affecting more than 10 million children nationwide - about one in every seven school-aged kids. In some communities - particularly low-income communities and communities of color - as many as one in four children suffer from asthma.

Kids in these high-risk communities are exposed daily to countless environmental hazards: exhaust-spewing cars, trucks and buses on nearby highways; unregulated industrial plants; and dilapidated schools with poor ventilation and mold.

"Too many kids in poor communities are forced to breathe unhealthy air from the moment they get up to the moment they go to sleep," said Judith Bell, president of PolicyLink. "We must eliminate the environmental asthma triggers that are leaving millions of our children gasping for air."

Fixing these problems will require the concerted partnership of community organizations and policymakers. The report builds on the innovative efforts to combat asthma triggers by more than a dozen organizations nationwide.

"All of California's kids should be able to grow and learn in healthy environ
'/>"/>

SOURCE PolicyLink
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Paramed Systems Achieves Significant Business Milestone in the Offshore Oil and Gas Evacuation Market
2. Innolife Pharma Provides Initial Update on Negotiations for Significant Product Joint Venture
3. U.S. Patent Office Allows Another Significant VNUS Patent
4. Ohio Health Care Association Elects North Canton Long-Term Care Provider as President
5. Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms
6. Researchers Find Lubricant Doesnt Hinder Fertility
7. Report raises C. diff concerns; yeast-based probiotic shown to help significantly reduce recurrence
8. 2008 Caregiving Conferences Come to Wayne County, Offering Free Workshops and Resources in Canton and Taylor Locations
9. HealthEdge Receives $13 Million Investment Commitment to Fund Significant Growth
10. Seattle-Based Law Firm Williams Kastner Receives Significant Defense Verdict in Trade Secret Business Litigation Case
11. Baxa Environmental Program Nets Significant Results
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation 2Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation 3Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation 4Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 2Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 3Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 4Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 5Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 6